Rick Doblin: MDMA for PTSD

MDMA remains a strictly regulated substance with extensive global history of use that provides significant data on its safety profile. Rather than repeating costly and redundant government studies, the current research path focuses on targeted, small-scale clinical trials investigating the specific efficacy and safety of the compound for conditions like PTSD. With an estimated funding requirement of 10 million dollars spread over a decade, this financial threshold is attainable through a non-profit model driven by public donations. These efforts focus on bridging the gap between historical prohibition and potential future medical integration.